Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing
Apogee Therapeutics is advancing towards a pivotal trial for its eczema treatment, zumilokibart. The drug has shown promising results in Phase 2b trials, with a dosing schedule of 2-4 times per year. The collaboration with Blackstone has also provided significant funding to support its development.
- ▪Apogee Therapeutics, Inc. is rated as a Buy based on the potential of zumilokibart for atopic dermatitis.
- ▪The Phase 2b results indicate that zumilokibart's efficacy is comparable to leading biologics.
- ▪The drug's unique dosing schedule of 2-4 doses per year is a key differentiator in its market potential.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909778-apogee-therapeutics-charging-toward-pivotal-eczema-trial-with-extended-dosing"},"author":{"@type":"Person","name":"Stephen…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
